Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC